Edition:
United States

Analyst Research

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AbbVie Inc files new drug submission to health canada for its investigational, all-oral, interferon-free therapy for treatment of hepatitis C


Thursday, 22 May 2014 07:45am EDT 

AbbVie Inc:Filed New Drug Submission (NDS) to Health Canada seeking approval for company's investigational, all-oral, interferon-free regimen for treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including patients with cirrhosis.Says NDS is supported by data from largest all-oral, interferon-free clinical program in GT1 patients conducted to date,(1) with six Phase III studies that included more than 2,300 patients in over 25 countries. 

Company Quote

61.44
0.44 +0.72%
4:02pm EDT